eFFECTOR Therapeutics (EFTR) Stock Forecast, Price Target & Predictions
EFTR Stock Forecast
eFFECTOR Therapeutics stock forecast is as follows: an average price target of $5.50 (represents a 1374900.03% upside from EFTR’s last price of -) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
EFTR Price Target
The average price target for eFFECTOR Therapeutics (EFTR) is $5.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $1.00. This represents a potential 1374900.03% upside from EFTR's last price of -.
EFTR Analyst Ratings
According to 2 Wall Street analysts, eFFECTOR Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for EFTR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
eFFECTOR Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 04, 2024 | - | Stifel Nicolaus | $10.00 | $2.96 | 237.84% | 2499900.06% |
| Jan 09, 2023 | - | JMP Securities | $1.00 | $0.44 | 127.32% | 249900.01% |
The latest eFFECTOR Therapeutics stock forecast, released on Apr 04, 2024 by Stifel Nicolaus company, set a price target of $10.00, which represents a 237.84% increase from the stock price at the time of the forecast ($2.96), and a 2499900.06% increase from EFTR last price (-).
eFFECTOR Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | - | - | - |
| Upside/Downside | -100.00% | -100.00% | 2499900.06% |
In the current month, the average price target of eFFECTOR Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to eFFECTOR Therapeutics's last price of -. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 09, 2023 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Jan 06, 2023 | Credit Suisse | Outperform | Outperform | Hold |
| Nov 17, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
eFFECTOR Therapeutics's last stock rating was published by JMP Securities on Jan 09, 2023. The company gave EFTR a "Market Outperform" rating, the same as its previous rate.
eFFECTOR Therapeutics Financial Forecast
eFFECTOR Therapeutics Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $664.40K | $802.75K | $420.00K | $280.00K | $100.00K |
| High Forecast | - | - | - | - | $664.40K | $802.75K | $420.00K | $280.00K | $100.00K |
| Low Forecast | - | - | - | - | $664.40K | $802.75K | $420.00K | $280.00K | $100.00K |
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - |
eFFECTOR Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. EFTR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
eFFECTOR Therapeutics EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| EBITDA | - | - | - | - | $-8.72M | - | - | $-7.21M | $-12.40M |
| Avg Forecast | - | - | - | - | $50.79K | $61.37K | $32.11K | $111.38K | $7.64K |
| High Forecast | - | - | - | - | $50.79K | $61.37K | $32.11K | $133.65K | $7.64K |
| Low Forecast | - | - | - | - | $50.79K | $61.37K | $32.11K | $89.10K | $7.64K |
| Surprise % | - | - | - | - | -171.73% | - | - | -64.69% | -1622.37% |
undefined analysts predict EFTR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than eFFECTOR Therapeutics's previous annual EBITDA (undefined) of $NaN.
eFFECTOR Therapeutics Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| Net Income | - | - | - | - | $-9.80M | - | - | $12.69M | $18.56M |
| Avg Forecast | $-3.65M | $-6.27M | $-7.08M | $-8.84M | $-24.30M | $-21.82M | $-16.46M | $6.33M | $-24.51M |
| High Forecast | $-3.65M | $-6.27M | $-7.08M | $-8.84M | $-24.30M | $-21.82M | $-16.46M | $7.60M | $-24.51M |
| Low Forecast | $-3.65M | $-6.27M | $-7.08M | $-8.84M | $-24.30M | $-21.82M | $-16.46M | $5.06M | $-24.51M |
| Surprise % | - | - | - | - | 0.40% | - | - | 2.00% | -0.76% |
eFFECTOR Therapeutics's average Quarter net income forecast for Jul 22 is $-16.46M, with a range of $-16.46M to $-16.46M. EFTR's average Quarter net income forecast represents a -229.72% decrease compared to the company's last Quarter net income of $12.69M (Mar 22).
eFFECTOR Therapeutics SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| SG&A | - | - | - | - | $2.75M | - | - | $3.44M | $6.32M |
| Avg Forecast | - | - | - | - | $1.99M | $2.41M | $1.26M | $840.69K | $300.25K |
| High Forecast | - | - | - | - | $1.99M | $2.41M | $1.26M | $840.69K | $300.25K |
| Low Forecast | - | - | - | - | $1.99M | $2.41M | $1.26M | $840.69K | $300.25K |
| Surprise % | - | - | - | - | 1.38% | - | - | 4.09% | 21.05% |
eFFECTOR Therapeutics's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to EFTR last annual SG&A of $2.75M (Dec 22).
eFFECTOR Therapeutics EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | - | - | - | - | 1 |
| EPS | - | - | - | - | $-0.24 | - | - | $0.31 | $0.46 |
| Avg Forecast | $-0.90 | $-1.53 | $-1.74 | $-2.17 | $-5.95 | $-5.35 | $-4.03 | $-5.93 | $-6.01 |
| High Forecast | $-0.90 | $-1.53 | $-1.74 | $-2.17 | $-5.95 | $-5.35 | $-4.03 | $-5.93 | $-6.01 |
| Low Forecast | $-0.90 | $-1.53 | $-1.74 | $-2.17 | $-5.95 | $-5.35 | $-4.03 | $-5.93 | $-6.01 |
| Surprise % | - | - | - | - | 0.04% | - | - | -0.05% | -0.08% |
According to 0 Wall Street analysts, eFFECTOR Therapeutics's projected average Quarter EPS for Jul 22 is $-4.03, with a low estimate of $-4.03 and a high estimate of $-4.03. This represents a -1400.63% decrease compared to EFTR previous annual EPS of $0.31 (Mar 22).
EFTR Forecast FAQ
Is eFFECTOR Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, eFFECTOR Therapeutics (EFTR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of EFTR's total ratings.
What is EFTR's price target?
eFFECTOR Therapeutics (EFTR) average price target is $5.5 with a range of $1 to $10, implying a 1374900.03% from its last price of $0.0004. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will eFFECTOR Therapeutics stock go up soon?
According to Wall Street analysts' prediction for EFTR stock, the company can go up by 1374900.03% (from the last price of $0.0004 to the average price target of $5.5), up by 2499900.06% based on the highest stock price target, and up by 249900.01% based on the lowest stock price target.
Can eFFECTOR Therapeutics stock reach $0?
EFTR's average twelve months analyst stock price target of $5.5 supports the claim that eFFECTOR Therapeutics can reach $0 in the near future.
What are eFFECTOR Therapeutics's analysts' financial forecasts?
eFFECTOR Therapeutics's analysts financial forecasts for the fiscal year (Dec 2022) are as follows: average revenue is $2.17M (high $2.17M, low $2.17M), average EBITDA is $255.65K (high $277.92K, low $233.38K), average net income is $-56.25M (high $-54.984M, low $-57.516M), average SG&A $6.51M (high $6.51M, low $6.51M), and average EPS is $-21.266 (high $-21.266, low $-21.266). EFTR's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-25.836M (high $-25.836M, low $-25.836M), average SG&A $0 (high $0, low $0), and average EPS is $-6.33 (high $-6.33, low $-6.33).